التفاصيل البيبلوغرافية
| العنوان: |
Can plasma vitamin C predict survival in stage IV colorectal cancer patients? Results of a prospective cohort study |
| المؤلفون: |
Temraz, Sally, Jabbour, Jana, Nassar, Farah, El Helou, Remie, Hadla, Ruba, Mezher, Maria, El Lakkiss, Ahmed, Charafeddine, Maya, Nasr, Rihab, Shamseddine, Ali |
| المصدر: |
Frontiers in Nutrition ; volume 10 ; ISSN 2296-861X |
| بيانات النشر: |
Frontiers Media SA |
| سنة النشر: |
2023 |
| المجموعة: |
Frontiers (Publisher - via CrossRef) |
| مصطلحات موضوعية: |
Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Food Science |
| الوصف: |
Background and Aims In light of the inconclusive evidence on the association between vitamin C status and colorectal cancer (CRC) outcome, this study assessed the prognostic value of vitamin C in participants with metastatic CRC (mCRC). Methods Adults with mCRC and cancer-free controls were recruited in this prospective cohort study to allow for comparison of vitamin C levels with healthy individuals from the same population. Sociodemographic, lifestyle, medical variables, BRAF and KRAS mutations, as well as Vitamin C plasma level and food intake were evaluated. Predictors of diminished vitamin C level were assessed via multivariate logistic regression. Mortality and progression free survival (PFS) among mCRC participants were analyzed based on plasma vitamin C level. Results The cancer group ( n = 46) was older (mean age: 60 ± 14 vs. 42 ± 9.6, p = 0.047) and included more males (29% vs. 19%, p < 0.001) than the cancer-free group ( n = 45). There was a non-significant difference in the vitamin C intake between the two groups; however, the mean plasma vitamin C level was lower in the cancer group (3.5 ± 3.7 vs. 9.2 ± 5.6 mg/l, p < 0.001). After adjusting for age and gender, the cancer group was more likely to be deficient compared to the cancer-free group [Adjusted Odds Ratio (95%CI): 5.4 (2.1–14)]. There was a non-significant trend for higher mortality in the vitamin C deficient cancer group (31% vs. 12%, p = 0.139). PFS did not differ based on vitamin C deficiency and patients with BRAF and KRAS mutations did not have significant differences in vitamin C levels. Conclusion mCRC patients have lower plasma vitamin C levels than healthy controls. The trend toward higher mortality in the vitamin C deficient cancer group was not statistically significant. Whether this phenomenon affects survival and response to treatment warrants further exploration in phase III clinical trials. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
unknown |
| DOI: |
10.3389/fnut.2023.1110405 |
| DOI: |
10.3389/fnut.2023.1110405/full |
| الإتاحة: |
https://doi.org/10.3389/fnut.2023.1110405Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.BDD091C4 |
| قاعدة البيانات: |
BASE |
